T1	Participants 42 91	patients with moderate-to-severe plaque psoriasis
T2	Participants 329 452	197 patients with moderate-to-severe plaque psoriasis were randomized to tofacitinib 2, 5 or 15 mg twice daily, or placebo.
T3	Participants 709 783	clinically important responders (CIR) (within-patient change) for the ISS.
T4	Participants 1150 1261	patients receiving tofacitinib reached ≥30% improvement versus 29.4% of patients receiving placebo (p < 0.0001)
